Physician profile
Michelle Robison
NPI 1578555835
$6,977.30
in general payments reported to CMS, 2019-2025
19 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $463 · 2021: $494 · 2022: $1,395 · 2023: $896 · 2024: $761 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,426.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,658.86 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Alphagan P |
| Allergan, INC. | $882.30 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $628.58 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $595.27 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $575.97 | 2019-2025 | Rocklatan, Clareon Panoptix Pro, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $480.94 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $422.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $400.78 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $293.71 | 2019-2021 | |
| Glaukos Corporation | $264.04 | 2020-2025 | Istent Infinite, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Idosetr |
| Tarsus Pharmaceuticals, INC. | $238.93 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $144.40 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $121.83 | 2019 | |
| Thea Pharma INC. | $85.56 | 2024-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $65.57 | 2020-2024 | Dextenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $55.50 | 2025 | Oxervate |
| Shire North American Group INC | $43.38 | 2019 | |
| Sight Sciences, INC. | $12.76 | 2019 | |
| Iridex Corporation | $6.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.